Learn languages naturally with fresh, real content!

Popular Topics
Explore By Region
OSE Immunotherapeutics, Inserm Transfert, and Nantes University partner to advance immunotherapies for cancer and autoimmune diseases.
OSE Immunotherapeutics, Inserm Transfert, and Nantes University have formed a partnership to advance immunotherapy research for cancer, inflammation, and autoimmune diseases.
The collaboration connects academic discoveries from Nantes University and Inserm with OSE’s development expertise, aiming to turn promising research into viable therapies.
Inserm Transfert will identify high-potential projects, providing funding and guidance to accelerate their progress.
The alliance strengthens the Immunotherapy Innovation Hub in Nantes and could expand this public-private model nationally.
It supports open research, technology transfer, and addressing unmet medical needs, reflecting a broader effort to bridge academic innovation with biotech industry capabilities in France.
OSE Immunotherapeutics, Inserm Transfert y la Universidad de Nantes se han asociado para avanzar en la inmunoterapia para el cáncer y las enfermedades autoinmunes.